**DEPARTMENT OF HEALTH & HUMAN SERVICES**

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 20-579/S-023

Boehringer Ingelheim Pharmaceuticals, Inc.
Attention: Kelly S. Billingham
Associate Director, DRA Product Labeling
900 Ridgebury Road/P.O. Box 368
Ridgefield, CT 06877

Dear Ms. Billingham:

Please refer to your supplemental new drug application dated October 30, 2007, received October 30, 2007, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Flomax® (tamsulosin hydrochloride) Capsules, 0.4 mg.

We also refer to your March 26, 2008, amendment

This "Changes Being Effected" supplemental new drug application provides for clarification to the existing information in the **CLINICAL PHARMACOLOGY** section and minor revisions to the **ADVERSE REACTIONS** section. In addition, revisions have been made to how the list of inactive ingredients in the **DESCRIPTION** section is worded.

We have completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA.* Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "**FPL for approved supplement NDA 20-579/S023**." Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
5515 Security Lane
HFD-001, Suite 5100
Rockville, MD 20852

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Olga Salis, Regulatory Project Manager, at (301) 796-0837.

Sincerely,

*{See appended electronic signature page}*

Scott Monroe, M.D.
Director
Division of Reproductive and Urologic Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

Enclosure

---

**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**

---

/s/

---

Scott Monroe

4/29/2008 06:44:23 PM